ERBB2 and breast carcinoma: The combination regimen of T-DM1/T-DXd and tucatinib for advanced breast cancer progression with prior taxane and trastuzumab showed acceptable toxicity and preliminary anti-tumor activity in patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases [74, 79, 120].